<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02991131</url>
  </required_header>
  <id_info>
    <org_study_id>18299</org_study_id>
    <secondary_id>SX1601</secondary_id>
    <nct_id>NCT02991131</nct_id>
  </id_info>
  <brief_title>Sivextro in Acute Bacterial Skin and Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global Observational Study</brief_title>
  <acronym>DART</acronym>
  <official_title>DART: &quot;SivextroÂ® in Acute Bacterial Skin anD Skin Structure Infection (ABSSSI) in Hospitalized Patients. A Global ObseRvational STudy.&quot;</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bayer</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This open-label, prospective, multi-center, non-interventional, observational, parallel
      cohort study intends to provide real life data on the treatment duration, effectiveness and
      safety of tedizolid and linezolid when treating ABSSSI hospitalized patients in a real
      practice setting.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective in this study is to assess the treatment duration in the real life in
      the 2 cohorts consisting of patients treated by 200 mg once daily IV/ PO tedizolid or treated
      by 600 mg twice daily IV/PO (Intravenous/ per oral) linezolid.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 13, 2017</start_date>
  <completion_date type="Anticipated">August 15, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 30, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The mean number of days that patients are treated in real life in the 2 cohorts consisting of patients treated by 200 mg once daily IV/PO tedizolid or treated by 600 mg twice daily IV/PO linezolid</measure>
    <time_frame>Up to 1 month</time_frame>
    <description>Duration of treatment is defined as the time interval from date of first administration of tedizolid or linezolid to the date of permanent discontinuation of tedizolid or linezolid, respectively.
The treatment is according to the recommendations written in the local product information.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of participants with adverse events</measure>
    <time_frame>Up to 1 month</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with investigator-assessed clinical response</measure>
    <time_frame>Up to 1 month</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Abscess</condition>
  <condition>Cellulitis</condition>
  <condition>Erysipelas</condition>
  <condition>Wound Infection</condition>
  <arm_group>
    <arm_group_label>Tedizolid</arm_group_label>
    <description>Hospitalized ABSSSI patients treated by tedizolid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Linezolid</arm_group_label>
    <description>Hospitalized ABSSSI patients treated by linezolid</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tedizolid (Sivextro, BAY 11-70438)</intervention_name>
    <description>Anti-infective agent</description>
    <arm_group_label>Tedizolid</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Linezolid</intervention_name>
    <description>Linezolid</description>
    <arm_group_label>Linezolid</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Hospitalized patients
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Adult female and male in-patients with clinical diagnosis compatible with ABSSSI
             (cellulitis/erysipelas, major skin abscess or wound infections) with a clinical
             suspicion of infection by Gram positive bacteria (with or without laboratory
             confirmation).

          -  Patients for whom the decision to initiate treatment with tedizolid phosphate or
             linezolid was made as per physician's routine treatment practice.

          -  Signed informed consent.

        Exclusion Criteria:

          -  Patients participating in an investigational program with interventions outside of
             routine clinical practice.

          -  Patients who have been enrolled in this study before.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bayer Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Bayer</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Bayer Clinical Trials Contact</last_name>
    <email>clinical-trials-contact@bayer.com</email>
  </overall_contact>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Colombia</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Philippines</country>
      </address>
    </facility>
    <status>Withdrawn</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Saudi Arabia</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <address>
        <city>Multiple Locations</city>
        <country>United Arab Emirates</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Colombia</country>
    <country>Mexico</country>
    <country>Philippines</country>
    <country>Russian Federation</country>
    <country>Saudi Arabia</country>
    <country>Singapore</country>
    <country>United Arab Emirates</country>
  </location_countries>
  <removed_countries>
    <country>Brazil</country>
  </removed_countries>
  <link>
    <url>http://www.fda.gov/cder/drug/DrugSafety/DrugIndex.htm</url>
    <description>Click here and search for drug information provided by the FDA.</description>
  </link>
  <link>
    <url>http://www.fda.gov/medwatch/safety.htm</url>
    <description>Click here and search for information on any recalls, market or product safety alerts by the FDA which might have occurred with this product.</description>
  </link>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 9, 2016</study_first_submitted>
  <study_first_submitted_qc>December 9, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 13, 2016</study_first_posted>
  <last_update_submitted>May 2, 2018</last_update_submitted>
  <last_update_submitted_qc>May 2, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 3, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Acute bacterial skin infection</keyword>
  <keyword>Acute Bacterial Skin and Skin Structure Infection (ABSSSI)</keyword>
  <keyword>Abscess</keyword>
  <keyword>Cellulitis</keyword>
  <keyword>Erysipelas</keyword>
  <keyword>Wound infection</keyword>
  <keyword>Methicillin resistant Staphylococcus aureus (MRSA)</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Wound Infection</mesh_term>
    <mesh_term>Abscess</mesh_term>
    <mesh_term>Cellulitis</mesh_term>
    <mesh_term>Erysipelas</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Linezolid</mesh_term>
    <mesh_term>Torezolid</mesh_term>
    <mesh_term>Torezolid phosphate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

